Ciproflox-dexameth otic susp 7.5ML
Ended Awarded
- Contract number
- SPE2DB25FJRT4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,715
Award facts
- Contract value 100% obligated
- $14,715.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ciprofloxacin-Dexamethasone Otic Suspension (7.5 mL) with a ceiling value of $14,715.38. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor agreement valued through December 2026 that supports global pharmaceutical supply to military healthcare programs worldwide. Performance will be completed by August 15, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania.
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor serving Defense Health Agency, U.S. Coast Guard, and military healthcare systems. The company maintains an extensive portfolio of federal contract awards through the DLA Medical Supply Chain, delivering a comprehensive range of pharmaceuticals including antibiotics, specialty medications, vaccines, and medical devices across multiple therapeutic domains. The Ciprofloxacin-Dexamethasone otic suspension is an antibiotic-corticosteroid combination typically used for ear infection treatment in military medical settings, consistent with the company's established role in supporting military healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FJRT4?
SPE2DB25FJRT4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 14, 2025.
How much is contract SPE2DB25FJRT4 worth?
The government has obligated $14,715 on SPE2DB25FJRT4.
Is contract SPE2DB25FJRT4 an order under another contract?
Yes. SPE2DB25FJRT4 is a delivery order under SPE2DB22D2005, an indefinite delivery contract.
Was contract SPE2DB25FJRT4 competed?
The extent of competition for SPE2DB25FJRT4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award